Dexmedetomidine mitigate acute lung injury by inhibiting IL-17-induced inflammatory reaction.

Interleukin-17 (IL-17) is considered to play an important role in the pathogenesis of a number of inflammatory conditions. Previous studies demonstrated that intranasal injections of IL-17 resulted in pulmonary inflammation and lung damage, we therefore hypothesize that dexmedetomidine, a potent α2 adrenergic receptor agonist that shows anti-inflammation effects in several animal models of inflammation, would attenuate IL-17 induced lung injury. We examined the lung damage using a histological approach, and assessed the number of lung-infiltrating neutrophils in the bronchoalveolar lavage fluid. We then compared the production of selected cytokines by measuring their serum concentration after various treatments. Finally, we evaluated the expression of selected inflammatory genes and activation of NF-κB in the lung epithelial cells, using real-time PCR and western blot assay, respectively. In every aspect of pulmonary inflammation investigated, dexmedetomidine significantly and dose-dependently attenuated the inflammatory effects of IL-17. Our results not only give a comprehensive description of the protective action of dexmedetomidine on IL-17 induced acute lung injury, but also provide insights to the underlying cellular and molecular mechanisms. [ABSTRACT FROM AUTHOR]